Antibodies Against Botulinum Neurotoxin Type A as a Cause of Treatment Failure After the First Detrusor Injection

Urology

Volumn 69, Issue 3, 2007, Pages 575.e13-575.e15

  Schulte Baukloh, Heinrich ^a   Bigalke, Hans ^b   Heine, Gert ^a   Pape, Daniela ^a   Stuerzebecher, Burkard ^a   Miller, Kurt ^a   Knispel, Helmut H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; TOXIN ANTIBODY;

AGED; ANAMNESIS; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BLADDER MUCOSA; CASE REPORT; CLINICAL FEATURE; CYSTOSCOPY; FEMALE; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PRIORITY JOURNAL; RESIDUAL URINE; SPHINCTER; TREATMENT FAILURE; URODYNAMICS;

EID: 33947244374     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.01.030     Document Type: Article

References (13)

1. Dykstra D.D., Sidi A.A., Scott A.B., et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988) 919-922
2. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
3. Chancellor M., O'Leary M., Erickson J., et al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 169 suppl 4 (2003) 351
4. Schulte-Baukloh H., Weiss C., Stolze T., et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48 (2005) 984-990
5. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19 suppl 8 (2004) S92-S100
6. Schulte-Baukloh H., Weiss C., Stolze T., et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66 (2005) 82-87
7. Goschel H., Wohlfarth K., Frevert J., et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 147 (1997) 96-102
8. Dressler D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 4 suppl 2 (1997) S67-S70
9. Kessler K.R., Skutta M., Benecke R., and German Dystonia Study Group. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety and antibody frequency. J Neurol 246 (1999) 265-274
10. Jankovic J., Vuong K.D., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186-1188
11. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 48 (2002) 26-29
12. Dressler D., Dirnberger G., Bhatia K.P., et al. Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 15 (2000) 973-976
13. Dykstra D., Enriques A., and Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J 14 (2003) 424-426